The Lung Immune Prognostic Index, based on NLR and LDH, was excellent in predicting the prognosis of patients with advanced NSCLC who received anti–PD-1/PD-L1 therapy (Sorich et al., 2019). Here, PDCD1 is linked to non-small cell lung carcinoma.